Definium Therapeutics (NASDAQ:DFTX) Trading 8.3% Higher – Time to Buy?

Definium Therapeutics, Inc. (NASDAQ:DFTX) shares were up 8.3% during trading on Tuesday . The stock traded as high as $17.22 and last traded at $17.06. Approximately 1,438,534 shares traded hands during trading, a decline of 27% from the average daily volume of 1,983,315 shares. The stock had previously closed at $15.75.

Analyst Ratings Changes

A number of equities research analysts recently commented on DFTX shares. Royal Bank Of Canada lifted their target price on Definium Therapeutics from $20.00 to $36.00 and gave the stock an “outperform” rating in a report on Friday, January 23rd. Cantor Fitzgerald reiterated an “overweight” rating on shares of Definium Therapeutics in a research report on Monday, February 2nd. Chardan Capital upgraded Definium Therapeutics to a “strong-buy” rating in a research report on Wednesday, November 19th. Needham & Company LLC reaffirmed a “buy” rating on shares of Definium Therapeutics in a research note on Monday, January 5th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Definium Therapeutics in a research note on Thursday, January 22nd. Two research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $35.22.

Definium Therapeutics Stock Performance

The company has a current ratio of 3.30, a quick ratio of 3.30 and a debt-to-equity ratio of 0.31. The firm’s fifty day moving average price is $15.07 and its 200 day moving average price is $12.49. The stock has a market capitalization of $1.70 billion, a price-to-earnings ratio of -8.47 and a beta of 2.57.

Insider Buying and Selling at Definium Therapeutics

In related news, CEO Robert Barrow sold 25,791 shares of Definium Therapeutics stock in a transaction dated Friday, December 26th. The stock was sold at an average price of $13.15, for a total value of $339,151.65. Following the completion of the transaction, the chief executive officer directly owned 778,477 shares in the company, valued at approximately $10,236,972.55. This trade represents a 3.21% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Mark Sullivan sold 11,276 shares of the firm’s stock in a transaction dated Friday, December 26th. The stock was sold at an average price of $13.15, for a total transaction of $148,279.40. Following the completion of the transaction, the insider directly owned 282,576 shares in the company, valued at $3,715,874.40. This represents a 3.84% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 42,667 shares of company stock worth $561,071. 2.26% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Marshall Wace LLP grew its holdings in Definium Therapeutics by 31.9% during the second quarter. Marshall Wace LLP now owns 3,421,224 shares of the company’s stock worth $22,204,000 after purchasing an additional 828,067 shares during the period. Geode Capital Management LLC grew its position in shares of Definium Therapeutics by 4.0% during the 2nd quarter. Geode Capital Management LLC now owns 1,733,454 shares of the company’s stock worth $11,252,000 after purchasing an additional 66,663 shares in the last quarter. Persistent Asset Partners Ltd bought a new position in shares of Definium Therapeutics during the second quarter worth approximately $238,000. Stempoint Capital LP bought a new stake in shares of Definium Therapeutics during the 2nd quarter valued at $590,000. Finally, Diadema Partners LP acquired a new position in shares of Definium Therapeutics in the 2nd quarter valued at approximately $1,029,000. Institutional investors and hedge funds own 27.91% of the company’s stock.

About Definium Therapeutics

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.